Information was received from a foreign health care provider (hcp) via a manufacturer representative regarding a patient who received an unknown drug in an implantable pump for an unknown indication for use.It was reported an overdose experience/symptoms occurred after replacement.No further information was provided.Additional information was received.It was reported the pump was implanted on (b)(6) 2018 , and the event occurred on the same date.Prior to the pump replacement, there was concern regarding a possible unidentified fault in the pump system, as spasm control had been lost.It was stated the previous pump had been set to a dose of 900 mcg/day.Following implant of the new pump, they were concerned that if the unidentified problem had been corrected, then the previous dose of 900 mcg/day could result in overdose.The new pump was set to a reduced dose of 500 mcg/day, with arrangements to monitor the patient in the high dependency unit (hdu).The concentration of baclofen used was 3000 mcg/ml.At approximately 02:00, the patient's vital signs began to raise concern, and overdose symptoms began to emerge.The patient became hypotensive with systolic blood pressure less than 80, they were increasingly drowsy but arousable, and their lower limbs became totally flaccid to passive movement.Troubleshooting included the monitoring system which was set up prior to the incident occurring so that the emerging overdose situation was quickly spotted.The pump was switched to minimum rate for a period of approximately 5 hours.During this period, the lower limb muscle tone began to increase, blood pressure returned to the previous level, and the patient became wakeful.The infusion was then recommenced at a further reduced rate of 200 mcg/day.Pump logs were not available.No further complications were reported or anticipated.
|